Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given an average rating of “Moderate Buy” by the nineteen ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $37.56.

A number of analysts recently issued reports on the company. Truist Financial decreased their target price on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $8.40 on Friday. The stock’s 50-day moving average is $10.01 and its two-hundred day moving average is $13.90. Intellia Therapeutics has a 1 year low of $8.11 and a 1 year high of $28.23. The firm has a market cap of $869.54 million, a price-to-earnings ratio of -1.54 and a beta of 1.97.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 29,000 shares of company stock worth $352,551 in the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $25,000. Sterling Capital Management LLC increased its stake in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $40,000. Resona Asset Management Co. Ltd. purchased a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp grew its holdings in Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.